BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36522219)

  • 1. Contemporary approaches to the axilla in breast cancer.
    Thompson JL; Wright GP
    Am J Surg; 2023 Mar; 225(3):583-587. PubMed ID: 36522219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De-escalation of axillary surgery in patients outside Z0011 criteria.
    Giannakou A; Gooch J; Gergelis KR; Weiss A
    Surgery; 2023 Aug; 174(2):416-418. PubMed ID: 37156648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of omission of axillary dissection on adjuvant therapy in patients with metastatic sentinel lymph nodes according to the ACOSOG Z0011 criteria].
    Roosen A; Lousquy R; Bricou A; Delpech Y; Selz J; Le Maignan C; Bousquet G; Winterman S; Zelek L; Barranger E
    Gynecol Obstet Fertil; 2014 Jun; 42(6):409-14. PubMed ID: 24861437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of frozen section in sentinel lymph node biopsy for breast cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials.
    Lombardi A; Nigri G; Maggi S; Stanzani G; Vitale V; Vecchione A; Nania A; Amanti C
    Surgeon; 2018 Aug; 16(4):232-236. PubMed ID: 29329752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole breast radiotherapy in cN0 early breast cancer patients with pathological sentinel lymph nodes (pN1mic, pN1a) without axillary dissection: preliminary results of the observational LISEN trial.
    Ursini LA; Nuzzo M; Rosa C; Borgia M; Caravatta L; Di Tommaso M; Trignani M; Di Guglielmo FC; Ausili Cefaro G; Angelucci D; Muzi M; Martino G; Cianchetti E; Grossi S; Tavoletta S; Brocco D; Grassadonia A; Tinari N; Gildetti S; D'Ostilio N; Stuppia L; Porreca A; Di Nicola M; Genovesi D
    Strahlenther Onkol; 2022 Jul; 198(7):612-621. PubMed ID: 35499695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axillary lymph node treatment in breast cancer: an update.
    Williams PA; Suggs J; Mangana SH
    J Miss State Med Assoc; 2014 May; 55(5):145-7. PubMed ID: 25112128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolution of the sentinel node procedure in the treatment of breast cancer.
    Tvedskov TF
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients.
    Verheuvel NC; Voogd AC; Tjan-Heijnen VC; Roumen RM
    Eur J Surg Oncol; 2016 Aug; 42(8):1162-8. PubMed ID: 27265036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative predictors of high and low axillary nodal burden in Z0011 eligible breast cancer patients with a positive lymph node needle biopsy result.
    Lim GH; Upadhyaya VS; Acosta HA; Lim JMA; Allen JC; Leong LCH
    Eur J Surg Oncol; 2018 Jul; 44(7):945-950. PubMed ID: 29705286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Impact of the Z0011 Trial on the Omission of Axillary Dissection: A Retrospective Cohort Study.
    Shinzato JY; Serra KP; Eugeni C; Cabello C; Cardoso-Filho C; Zeferino LC
    Rev Bras Ginecol Obstet; 2021 Apr; 43(4):297-303. PubMed ID: 33784760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The State of Surgical Axillary Management and Adjuvant Radiotherapy for Early-stage Invasive Breast Cancer in the Modern Era.
    Mann JM; Wu X; Christos P; Nagar H
    Clin Breast Cancer; 2018 Aug; 18(4):e477-e493. PubMed ID: 29031423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trade-offs associated with axillary lymph node dissection with breast irradiation versus breast irradiation alone in patients with a positive sentinel node in relation to the risk of non-sentinel node involvement: implications of ACOSOG Z0011.
    Krishnan MS; Recht A; Bellon JR; Punglia RS
    Breast Cancer Res Treat; 2013 Feb; 138(1):205-13. PubMed ID: 23338762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omission of axillary lymph node dissection in patients with ypN+ breast cancer after neoadjuvant chemotherapy: A retrospective multicenter study (KROG 21-06).
    Park Y; Shin YS; Kim K; Shin KH; Chang JH; Kim SS; Jung JH; Park W; Kim H; Kim YB; Ahn SJ; Kim M; Kim JH; Cha HJ; Kim TG; Park HJ; Lee SY
    Eur J Surg Oncol; 2023 Mar; 49(3):589-596. PubMed ID: 36470801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
    Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
    Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
    Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
    Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
    Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH
    Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
    Yoo TK; Kang BJ; Kim SH; Song BJ; Ahn J; Park WC; Chae BJ
    Breast Cancer Res Treat; 2020 Jun; 181(2):403-409. PubMed ID: 32328848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.